The Ukrainian Antimonopoly Committee (AMCU) has recently filed a lawsuit against international tobacco giant Philip Morris International, accusing them of promoting unverified health risk information about their IQOS heated tobacco product.
The company has been accused of disseminating misleading information regarding the use of IQOS products, claiming they pose lower health risks compared to traditional cigarettes. This violation allegedly violates Article 151 of the Anti-Unfair Competition Law.
The AMCU case involves a consumer who used HEETS tobacco products manufactured by Philip Morris International for their IQOS product between 2018 and 2021. The consumer believed these products were a safer alternative to traditional cigarettes, but found no conclusive evidence to support this claim.
The committee stated that Phillip Morris did not provide them with documents to prove the validity of their statements made in Ukraine, including "completely switching to IQOS poses less risk to your health compared to continued smoking" and "IQOS emissions contain 95% less harmful chemicals than cigarettes.
The Association of Mineworkers and Construction Union (AMCU) believes that disseminating these claims without appropriate verification constitutes a violation of unfair competition laws by spreading misleading information.
The Ukrainian Ministry of Health has stated that international studies show that any tobacco heating product poses a danger and does not reduce the risk of smoking.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
